SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

CURIS INC
Date: Feb. 19, 2026 · CIK: 0001108205 · Accession: 0000000000-26-001698

Offering / Registration Process Regulatory Compliance Financial Reporting

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-293470

Date
February 19, 2026
Author
James E. Dentzer
Form
UPLOAD
Company
CURIS INC

Letter

February 19, 2026 James E. Dentzer Chief Executive Officer Curis, Inc. 128 Spring Street, Building C Suite 500 Lexington, MA 02421 Re:Curis, Inc. Registration Statement on Form S-3 Filed February 13, 2026 File No. 333-293470 Dear James E. Dentzer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Caroline Dotolo, Esq.

Show Raw Text
February 19, 2026
James E. Dentzer
Chief Executive Officer
Curis, Inc.
128 Spring Street, Building C Suite 500
Lexington, MA 02421
Re:Curis, Inc.
Registration Statement on Form S-3
Filed February 13, 2026
File No. 333-293470
Dear James E. Dentzer:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Caroline Dotolo, Esq.